VIDEO: Novel treatments show efficacy for fatty liver, cirrhosis

BOSTON — In this exclusive video from The Liver Meeting 2019, Manu Chakravarthy, MD, PhD, chief medical officer and senior vice president of Axcella Health, discusses positive study results from a nonalcoholic fatty liver disease therapy trial and a cirrhosis therapy trial.Chakravarthy first described the trial of AXA1125, which comprised 32 patients with comorbid NAFLD and type 2 diabetes.After 12 weeks of treatment, patients had a 55% increase in insulin-dependent glucose uptake into hepatocytes (P = .0002), a 40% decrease in free fatty acid release from adipocytes (P = .0052), alongRead More

Share on facebook
Share on twitter
Share on linkedin